Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - Exelixis/sanofi-aventis
Latest Information Update: 13 Feb 2012
Price :
$50
*
At a glance
- Originator Exelixis; sanofi-aventis
- Developer Exelixis; Sanofi
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Dec 2011 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 16 Nov 2010 Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010) (AACR-2010)
- 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)